Compugen reports Q2 2026 results, cash runway extended into 2029

Compugen Ltd. reported second quarter 2026 financial results on August 3, 2026, alongside updates on its immuno-oncology pipeline.

The company said its MAIA-ovarian trial, a sponsored randomized placebo-controlled adaptive platform study evaluating COM701 as maintenance monotherapy in second- and third-line relapsed platinum-sensitive ovarian cancer, remains on track for an interim analysis with median progression-free survival data expected by the first quarter of 2027.¹ Compugen also noted that it presented a trial-in-progress poster on MAIA-ovarian at the ESMO Gynaecological Cancers Congress held in Copenhagen during the quarter.¹

On the partnered side, AstraZeneca presented new data on rilvegostomig, the PD-1/TIGIT bispecific antibody it develops using Compugen's TIGIT component. At ASCO 2026, AstraZeneca reported an updated analysis from the GEMINI-Hepatobiliary study, marking the first overall survival readout for rilvegostomig, showing a median overall survival of 16.8 months compared with under 13 months in earlier first-line biliary tract cancer trials.¹ The company cautioned that longer follow-up and randomized data from the ongoing Phase 3 trial will be needed to confirm these results.¹ Separately, the Gilead-partnered GS-0321 Phase 1 dose-escalation trial continued to progress as planned.¹

Financially, Compugen held roughly $125.3 million in cash, cash equivalents, short-term bank deposits, and marketable securities as of June 30, 2026,¹ which it said should fund operations into 2029.¹ Quarterly revenue rose to approximately $2.6 million versus $1.3 million a year earlier,¹ while R&D expenses increased to about $6.3 million from $5.6 million.¹ Net loss for the quarter was approximately $7.0 million, or $0.07 per share, compared with a $7.3 million loss, or $0.08 per share, in the prior-year period.¹